StockData

Akebia Therapeutics vs CorMedix

AKBA and CRMD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AKBA and CRMD compare

CorMedix is the larger company, worth 3.3 times as much as Akebia Therapeutics ($364M against $111M).

CorMedix grew revenue faster over the last twelve months (281% versus 7.5% for Akebia Therapeutics).

CorMedix keeps more of each dollar of sales as profit, with a net margin of 40.5% compared with −13.5% at Akebia Therapeutics.

CorMedix scores higher on the StockData Score (13 against 6 for Akebia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAKBACRMD
Size and price
Market cap$111M$364M
Share price$0.400$4.67
Change, 1 year−76.0%−58.5%
Change, 5 years−85.0%−7.9%
Beta (5Y)1.200.49
Employees194191
StockData Score
Total score613 (better)
Valuation score01 (better)
Growth score23 (better)
Performance score24 (better)
Health score25 (better)
Dividend score00
Valuation
P/S0.5× (better)0.8×
P/B4.4×0.8× (better)
EV/EBITDA–0.5×
P/FCF2.8×1.5× (better)
FCF yield36.3%68.8% (better)
Growth
Revenue growth (TTM)7.5%281% (better)
Revenue growth, 5Y average−4.3%320% (better)
Net income growth (TTM)–266%
Profitability
Gross margin79.6%82.8% (better)
Operating margin−6.9%47.0% (better)
Net margin−13.5%40.5% (better)
FCF margin18.4%54.2% (better)
Return on equity−109%54.9% (better)
Return on invested capital–171%
Financial health
Debt / equity1.98 (better)0.00
Current ratio1.432.56 (better)
Altman Z-score−5.892.01 (better)
Piotroski F-score7 (better)5
Dividends and buybacks
Buyback yield–−0.28%
Shareholder yield0.00% (better)−0.28%
Ownership
Held by institutions39.7%56.5%
Held by insiders2.9%3.3%
Insider net buying, 12 months−$876K (better)−$1.6M
Short interest, % of float10.1%18.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.